Blockage of the EV‐Gas6/Axl pathway significantly suppresses EPC recruitment and tumour revascularization, which could be a potential therapy to enhance the efficacy of AA‐TKI against CRC (Figure 10e). The gene discussed is GAS6; the disease is neoplasm.